With coronavirus cases surging in the United States, the need for a vaccine is growing increasingly urgent, but federal officials have sought in recent days to reassure the public that the approval process for any potential vaccine will be thorough and transparent. Pfizer and BioNTech announced Wednesday that the latest data from their vaccine study indicates their shot is 95% effective, and they intend to formally apply for emergency authorization (EUA) in the U.S. within days. The companies claimed no serious side effects had been detected, and the most common problem was fatigue reported by 4% of participants. To read the full story.
Recent Posts
- Scientists Discover How Genetic Risk for Alcoholism Changes Brain Cell Behavior.
- What leaving World Health Organization would mean for US.
- Fears of devastation across NJ health, scientific research if Trump cuts proceed.
- Rutgers Health scores $686K grant to study effects of medicinal cannabis use.
- Bird Flu Basics From a Rutgers Health Infectious Disease Expert.
Categories
- Community (2,144)
- Covid (982)
- CTO Events (6)
- News (2,734)
- Pilots (21)